Transcatheter Embolization and Occlusion Devices Market Regional Analysis

As per transcatheter embolization and occlusion devices market outlook, North America led the market with 29.7% revenue share in 2022. Availability of advanced healthcare infrastructure, well-defined regulatory framework, and skilled healthcare professionals are the major drivers for TEO demand devices in this region. According to the Centers for Disease Control and Prevention (CDC), these devices are used in cases of migraine and muscle spasms; Each year, 454,000 people are diagnosed with atrial fibrillation. The market is characterized by a few major players, including Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC, who are continuously innovating and expanding their product offerings to meet the growing demand. 

As per transcatheter embolization and occlusion devices market analysis, Asia-Pacific is expected to grow at the fastest CAGR of 8.1% during the forecast period. The rapidly growing industry in emerging economies such as India, China and Malaysia attract cancer patients from all over the world. The region is also the most densely populated and has a large elderly population. According to a WHO report, 414 million people in Asia-Pacific are over the age of 60.40% of the population of Hong Kong and Japan is predicted to be over the age of 65 by 2050. These people are more likely to develop CVD, for which transcatheter embolization is a treatment which is not very difficult.